Navigation Links
ENDEAVOR IV Clinical Trial Meets Primary Endpoint

MINNEAPOLIS--(BUSINESS WIRE)--Jul 2, 2007 - Medtronic, Inc., (NYSE:MDT) today announced that a review of data from the ENDEAVOR IV Clinical Trial indicates that the trial has met its primary, non-inferiority endpoint.

The ENDEAVOR IV Clinical Trial is a randomized, single-blind trial evaluating the safety and efficacy of the Endeavor(TM) Drug Eluting Coronary Stent as compared to the TAXUS Paclitaxel-Eluting Coronary Stent System from Boston Scientific Corporation (NYSE:BSX). ENDEAVOR IV is evaluating 1,548 patients at 80 clinical centers in the United States, with a primary endpoint of Target Vessel Failure (TVF - a composite of cardiac death, myocardial infarction and target vessel revascularization) at nine months. Medtronic will submit these data to the U.S. Food and Drug Administration (FDA) in support of the Endeavor Pre-Market Approval (PMA) application and intends to present the final ENDEAVOR IV clinical trial data at the Transcatheter Cardiovascular Therapeutics (TCT) annual conference in Washington, DC, in October 2007.

"The Endeavor stent continues to demonstrate positive results for patients around the world," said Scott Ward, president of the CardioVascular business at Medtronic. "The Endeavor stent has produced excellent results across an extensive clinical program, with long-term clinical follow up extending to three and four years. We have the most comprehensive dossier of clinical data ever produced for a drug eluting stent application in the U.S., with more than 4,100 patients. The Endeavor stent will be reviewed by FDA at a panel this fall, and we continue to anticipate FDA approval later this calendar year."

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Caution: The Endeavor(TM) Drug Elut ing Coronary Stent is an investigational device. The device is limited by federal (or United States) law to investigational use only.

Any statements made about anticipated regulatory review or approval are forward-looking statements subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

Contact

Medtronic, Inc.
Public Relations:
Rob Clark, 763-505-2635
or
Investor Relations:
Martha Goldberg Aronson, 763-505-2694


'"/>




Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... , Sept. 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ... greatest aural experiences — and deliver these experiences as part ... help people feel and heal better. ... While nothing beats a walk, jog ... your mind, Life Environments™ is the next best thing when ...
Breaking Medicine Technology:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance ... research, education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. ... Sellati has more than 20 years of research experience with Lyme and other ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
(Date:9/21/2017)... ... , ... In addition to sticking with the new years ... and use natural alternatives for all house cleaning products, disinfectants, respiratory relief, and ... the new line of essential oils, are all 100% organic and natural. , ...
(Date:9/21/2017)... RICHMOND, Va. (PRWEB) , ... September 21, 2017 ... ... Richmond with a different approach to addiction recovery at a time when Virginia ... 1,420 deaths resulting from drug overdose, a staggering increase of 38 percent from ...
Breaking Medicine News(10 mins):